DUNEDIN, New Zealand – Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) today reports FY 26 results in a strategically significant year that has culminated, post balance date, in the achievement of a draft Medicare policy change

TruScreen Group Limited (NZX/ASX:TRU) (TruScreen or TRU or Company) is pleased to advise that further to the announcement of 21 May 2026 “TruScreen announces the opening of a NZ$2.9m capital raise”

Leading transportation technology services company EROAD Limited (NZX/ASX: ERD), today released its financial performance for the 12 months ended 31 March 2026 as it executes on its transformation plan to restore performance and deliver value

Auckland, 22 May 2026: EROAD Limited ("EROAD") is pleased to announce the appointment of Ryan Brosnahan as a Non-Executive Director of EROAD, effective 1 June 2026

Oceania Healthcare (NZX/ASX: OCA) delivered a record result, with sales volumes increasing 16%, Proforma Underlying EBITDA1 growing 20%, and net debt reducing by $121.4m. The result marks a step-change in performance

What does this mean for the outlook for the New Zealand and Australian stock markets?

If you have listed NZX and ASX investments and you are in the process of reassessing your holdings or wish to do so, our advisers at Equity Investment Advisers Limited are willing to assist. As you are no doubt aware most markets are fully priced, and som